

- Anomia, 177, 179, 197
Anopheles mosquitoes
 climate change and, 151e-4
 in lymphatic filariasis, 1418t
 in malaria transmission, 1368–1370, 1369f, 1371
- Anorectal (rectoanal) angle, 265, 265f
 Anorectal disorders, **1973**
 anal fissures, 1978
 anorectal abscess, 1977–1978, 1977f
C. trachomatis proctitis, 1168
 in Crohn's disease, 1953
 fecal incontinence. *See* Fecal incontinence
 fistula in ano, 1111, 1978
 hemorrhoidal disease. *See* Hemorrhoidal
 disease
 in HIV infection, 1257–1258, 1258f
 perianal skin tags, in IBD, 1958
 rectal prolapse. *See* Rectal prolapse
 solitary rectal ulcer syndrome, 277, 1957
 Anorectal manometry, 274
 Anorectum, 265, 265f
 Anorexia
 in appendicitis, 1987
 in elderly, 81
 enteral tube feeding in, 98e-3
 in gastric cancer, 534
 in terminally ill patient, 69t
 Anorexia nervosa, 259, **2719**
 Anorexiants, 1617t, 2396–2397, 2453
 Anosmia. *See* Olfactory disorders
 Anosognosia, 180, 2560, 2598
 Anovulation, 335
 Anoxic cerebral injury, in critically ill patient,
 1735
- ANP (atrial natriuretic peptide), 251, 310,
 332e-6f, 332e-9, 511
- Anserine bursitis, 2222, 2248
- Ant(s), stinging, 2749
- Antacids
 adverse effects of, 267, 269, 321
 drug interactions of, 41, 42t, 246e-1t, 246e-3t,
 939t
 for GERD, 263
 for internal radionuclide contamination,
 263e-6, 263e-6t
 for peptic ulcer disease, 1919–1920, 1920t
- Antagonistic pleiotropy, 94e-2
- Anterior cerebral artery
 lesion in territory of, 156, 178
 occlusion of, 2573, 2575f
 territory of, 2572f, 2574f
- Anterior chamber, eye, 40e-1
- Anterior choroidal artery, 2573–2574, 2575f
- Anterior dens dislocation, 441e-31f
- Anterior horn cell disorders, 154, 157
- Anterior ischemic optic neuropathy (AION),
 202, 202f
- Anterior pituitary. *See also* Pituitary gland
 disorders of
 insufficiency. *See* Hypopituitarism
 tumors. *See* Pituitary tumors (adenomas)
 hormone expression and regulation in,
 401e-1–4, 401e-1t. *See also specific
 hormones*
- Anterior spinal artery syndrome, 2652, 2655
- Anterocollis, 2620
- Anterograde amnesia, 182
- Anterolateral system, 158
- Anthracyclines
 adverse effects of, 103e-25, 380–381, 620t,
 621, 1562
 for breast cancer, 530
 for soft tissue sarcoma, 119e-2
 for thymoma, 123e-2
- Anthralin, 355t
- Anthrax
 in bioterrorism, 261e-2–3, 261e-2f
 chest x-ray in, 261e-3, 261e-4f
 clinical features of, 261e-2–3, 261e-3f, 261e-
 5t, 784
 cutaneous, 134t, 135, 261e-2, 261e-3f, 829
 diagnosis of, 261e-5t
 gastrointestinal, 261e-2
 inhalational, 261e-2–3, 784
 prevention of, 261e-3, 261e-5t
 treatment of, 261e-3, 261e-5t
- Anthrax vaccine, 261e-3
 Anthrax vaccine adsorbed, 261e-3
 Anthropometrics, 462
 Anthroposophic medicine, 14e-1t
- Anti-AChR antibodies, 372e-24t, 377e-4, 614t,
 2701, 2702t
- Anti-AMPA receptor antibodies, 617
- Anti-amphiphysin, 614t
- Antiandrogens. *See* Androgen deprivation
 therapy (ADT)
- Antiarrhythmics, **273e-5**. *See also specific drugs*
 actions of, 273e-5, 273e-6t
 adverse effects of, 267, 1467t, 1471t, 1480t
 classification of, 273e-5, 273e-6t
 intravenous dose range/primary indication,
 1479t
 oral dosing/primary indications, 1480t
 overdosage/poisoning with, 473e-13t
 for pain, 91t, 94
- Antibacterial drugs, **930**. *See also specific drugs
 and diseases*
 absorption of, 934–935
 actions of, 930–932, 931t, 932f
 adverse effects of, 936
C. difficile infections, 858
 in G6PD deficiency, 656t
 allergy to, 936
 for anaerobic gram-negative rods, 1101t
 approach to therapy with, 935–936
 concentration-dependent, 935
 distribution of, 935
 drug–drug interactions of, 936
 effects on microbiota, 86e-7
 empirical therapy with
 for acutely ill febrile patient, 779, 780t
 for community-acquired pneumonia, 807,
 808t
 for febrile neutropenia, 103e-23
 for fever of unknown origin, 141
 for infective endocarditis, 824
 for sepsis/septic shock, 1756, 1757t
 excretion of, 935
 inappropriate use of, 918, 1026
 for infections in cancer patient, 490–491
 metabolism of, 935
 pharmacodynamics of, 935, 935f
 pharmacokinetics of, 934–935, 935f
 prophylactic use of, 945, 945t
 for animal bite-wounds, 167e-3, 167e-3t
 for bronchiectasis, 1696
 for cancer patient, 492
 for chronic neutropenia, 423
 for dental procedures, 242
 for infective endocarditis, 826–827, 826t
 for transplant recipient, 925t, 927
 resistance to, **933**. *See also specific drugs*
 in anaerobic bacteria, 1101, 1101t
 genomics in detection of, 769t, 773–775
 in gram-negative bacteria, 807, 1026–1027
 in health care–associated infections, 918
 mechanisms of, 933
 in *S. pneumoniae*, 807
 selection of, 775
 stewardship of, 918, 945–946, 1026, 1027
 susceptibility testing, 150e-8
 time-dependent, 935
- Anti- β_2 -glycoprotein antibodies, 2131,
 2134–2135, 2135t, 2754t
- Antibody(ies). *See also* Immunoglobulin(s);
specific antibodies
 affinity maturation of, 372e-21
 blood group, 138e-1–2, 138e-1t
 for cancer treatment. *See* Cancer biologic
 therapy
 cytotoxic reactions of, 372e-29
 definition of, 372e-1
 drug-dependent, 727
 in neurologic paraneoplastic syndromes, 614,
 614t
 in parasitic infections, 245e-6, 245e-6t
 to T and B cells, 372e-30–31
- Antibody-dependent cell-mediated cytotoxicity
 (ADCC), 372e-1, 372e-6, 1244
- Antibody enhancement, 1244
- Antibody isotope switching, 372e-22
- Anticardiolipin antibodies (aCL), 2131, 2135t,
 2754t
- Anti-Caspr2 antibodies, 614t, 617
- Anti-CCP antibodies, 2141, 2142f
- Anticholinergics. *See also specific drugs*
 adverse effects of, 81, 167, 241, 1969
 for asthma, 1676–1677
 for COPD, 1705
 for irritable bowel syndrome, 1969
 for lower urinary tract symptoms, 7e-4
 for nausea and vomiting, 260, 260t
 overdosage/poisoning with, 473e-1, 473e-8t
- Anticholinesterase agents. *See* Cholinesterase
 inhibitors
- Anticipation, 440
- Anticoagulant(s), **749**
 for acute limb ischemia, 1646
 for brain tumors, 598
 dental procedures and, 241–242
 drug interactions of, 43
 for DVT, 47, 1634–1635, 1635t
 intracranial hemorrhage due to, 2584
 for myocardial infarction, 1597, 1598t, 1606
 in noncardiogenic stroke prevention, 2571
 oral, 754, 756t, 1889t. *See also specific drugs*
 parenteral. *See specific drugs*
 for pulmonary embolism, 1634–1635, 1635t
 reversal of, 738
 for stroke prevention in cardiac disease, 1485t,
 1487, 1488, 2566t, 2570–2901
 for suppurative thrombophlebitis, 906
- Anticonvulsants. *See* Antiepileptic drugs (AEDs)
- Anti-CRMP5 antibody, 614t, 616
- Anti-dandruff shampoo, 347
- Antidepressants. *See also specific drugs*
 actions of, 465e-2
 adverse effects management, 2711t
 adverse effects of, 65, 81, 267, 378, 380, 2710t
 for depression, 2710t, 2716–2717, 2716f
 for fatigue, 153
 for insomnia, 65, 191
 for irritable bowel syndrome, 1969
 for pain, 91t, 93–94, 93t, 2672
 for personality disorders, 2720
- Antidiuretic hormone (ADH). *See* Arginine
 vasopressin (AVP)
- Antidotes, 473e-7. *See also specific drugs/poisons*
- Antidote Treatment Nerve Agent Autoinjector
 (ATNAA), 262e-6, 262e-6f
- Anti-DPPX antibodies, 614t, 617
- Antidromic AV reentry, 1482, 1483f
- Anti-dsNDA antibody, 2126t, 2131
- Antiemetics, 260, 260t
- Antiepileptic drugs (AEDs). *See also specific
 drugs*
 action of, 2548
 adverse effects of
 cobalamin malabsorption, 644t
 cross-sensitivity and, 385
 genetic considerations in, 385
 hair loss, 380
 hypersensitivity, 382. *See also* Drug-induced
 hypersensitivity syndrome (DIHS)
 incidence of, 377
 neurologic, 2553–2555t
 osteoporosis, 2492
 SJS/TEN, 383. *See also* Stevens-Johnson
 syndrome (SJS); Toxic epidermal
 necrolysis (TEN)
 systemic, 2553–2555t
 vitamin D deficiency, 2485
 for brain abscess, 902
 for brain tumors, 598
 breast-feeding and, 2559
 discontinuation of, 2556
 dosage monitoring, 327
 drug interactions of, 246e-10, 1793,
 2553–2555t, 2559
 for focal seizures, 2552, 2556
 for generalized seizures, 2556